Percutaneous Tibial Nerve Stimulation (PTNS) for Voiding Dysfunction

Number 7.01.553

Effective Date March 31, 2015

Revision Date(s) 03/10/15

Replaces 7.01.106


Percutaneous tibial nerve stimulation (PTNS) may be considered medically necessary as a treatment for non-neurogenic overactive bladder (OAB) syndrome when ALL of the following criteria are met:

  • All other causes for OAB have been ruled out (e.g. anatomical variances, infections) AND
  • Symptoms of OAB (e.g. urinary urgency, urge incontinence, urinary frequency) are present for at least 3 months AND
  • The member has tried and failed at least 12 weeks of conservative medical management that includes:
  • Behavioral therapy (see Policy Guidelines) AND
  • Pharmacotherapy, unless contraindicated (e.g. oral/transdermal anticholinergic and/or antimuscarinics medications

Percutaneous tibial nerve stimulation (PTNS) is considered investigational for:

• All other voiding dysfunction conditions including but not limited to urinary incontinence

• Fecal incontinence

Related Policies


Pelvic Floor Stimulation as a Treatment of Urinary and Fecal Incontinence


Electrical Stimulation Devices


Percutaneous Electrical Nerve Stimulation (PENS) and Percutaneous Neuromodulation Therapy (PNT)


Sacral Nerve Neuromodulation/Stimulation


Autologous Fat Grafting to the Breast and Adipose-derived Stem Cells

Policy Guidelines

Behavioral therapy interventions

Behavioral therapy generally consists of the following components tailored to the individual patient’s needs:

  • Bladder training, including timed voiding and inhibition of urge impulses
  • Pelvic floor muscle training, including instruction and monitoring by health professional and active regular practice by the patient.
  • Fluid management, such as restriction of fluid and/or caffeine intake.

Weight loss has been effective in reducing symptoms of overactive bladder (OAB), but is not generally considered part of behavioral treatment.

Pharmacotherapy interventions

Anticholinergic/anti-muscarinic drugs are the commonly used medications for OAB (e.g. darifenacin, fesoterodine, oxybutynin, tolterodine, solifenacin). Many of these medications come in formulations other than immediate release (IR) that may help with the side effect of dry mouth, such as extended release (ER) or transdermal patch (TDS). Because these medications cause pronounced dry mouth, this may be a barrier to adherence or may be contraindicated (e.g. patients with narrow-angle glaucoma).

A failure of conservative therapy is defined as OAB symptoms that continue to impact function and/or daily quality of life after the patient has actively participated in at least 12 weeks of a behavioral treatment program and medication plan, unless contraindicated.




Posterior tibial neurostimulation, percutaneous needle electrode, single treatment, includes programming

CPT codes range of 64553-64565 for percutaneous implantation of neurostimulator electrode array do not apply since PTNS uses percutaneously inserted needles and wires not implanted electrodes.

CPT 64590 Insertion or replacement of peripheral or gastric neurostimulator pulse generator or receiver, direct or inductive coupling, does not apply. The stimulation devices used in PTNS are not implanted.


Voiding dysfunction manifested as overactive bladder symptoms is characterized by a strong urge to urinate (urinary urgency) that may prevent a patient from getting to the toilet before leaking urine (urge incontinence). Percutneous tibial nerve stimulation (PTNS, also known as posterior tibial nerve stimulation) is a technique of electrical neuromodulation used primarilyfor treating voiding dysfunction. The tibial nerve is stimulated using a fine-needle electrode inserted slightly above the ankle, and low-voltage electrical current is delivered. The recommended course of treatment is 12 weekly 30-minute sessions followed by an individualized maintenance schedule.


Altering the function of the posterior tibial nerve with PTNS is believed to improve voiding function and control. While the posterior tibial nerve is located near the ankle, it is derived from the lumbar-sacral nerves (L4-S3), which control the bladder detrusor and perineal floor. Voiding dysfunction includes urinary frequency, urgency incontinence, and nonobstructive retention. Common causes of voiding dysfunction are pelvic floor dysfunction (e.g., from pregnancy, childbirth, surgery), inflammation, medication (e.g., diuretics and anticholinergics), obesity, psychogenic factors, and disease (e.g., multiple sclerosis, spinal cord injury, detrusor hyperreflexia, diabetes with peripheral nerve involvement). The current FDA-cleared indication for PTNS is overactive bladder (OAB), which is defined as the presence of urinary urgency, with or without urgency urinary incontinence, that is usually accompanied by frequency and nocturia and is not associated with urinary tract infections or other known pathology.

The procedure for PTNS consists of the insertion of a needle above the medial malleolus into the posterior tibial nerve followed by the application of low-voltage (10 mA, 1-10 Hz frequency) electrical stimulation that produces sensory and motor responses (i.e., a tickling sensation and plantar flexion or fanning of all toes). Noninvasive PTNS has also been delivered with surface electrodes. The recommended course of treatment is an initial series of 12 weekly office-based treatments followed by an individualized maintenance treatment schedule.

PTNS is less invasive than traditional sacral nerve neuromodulation (see Related Policies), which has been successfully used in the treatment of urinary dysfunction but requires implantation of a permanent device. In sacral root neuromodulation, an implantable pulse generator that delivers controlled electrical impulses is attached to wire leads that connect to the sacral nerves, most commonly the S3 nerve root that modulates the neural pathways controlling bladder function.

PTNS is not cleared by FDA for treating fecal incontinence; however, the treatment has been proposed for this purpose. The manufacturer recommends a course of treatment for fecal incontinence similar to the one used to treat OAB; an initial course of 12 weekly sessions of tibial nerve stimulation followed by a personalized schedule of follow-up treatments.

Regulatory Status

In July 2005, the UrgentĀ® PC Neuromodulation System (Uroplasty Inc.) received 510(k) marketing clearance from the U.S. Food and Drug Administration (FDA) for percutaneous tibial nerve stimulation to treat patients suffering from urinary urgency, urinary frequency, and urge incontinence. The device was cleared as a class II ‘‘nonimplanted, peripheral nerve stimulator for pelvic floor dysfunction” because it was considered to be substantially equivalent to the previously cleared percutaneous Stoller afferent nerve system (PerQ SANS System) in 2001 (K992069, UroSurge Inc.). In 2010, the cleared indication was changed to “overactive bladder (OAB) and associated symptoms of urinary urgency, urinary frequency, and urge incontinence.”

The Urgent PC Neuromodulation System is not FDA-cleared for other indications, such as the treatment of fecal incontinence.


Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply. This policy does not apply to Medicare Advantage.

Benefit Application



This policy was created in February 2014 based on a BlueCross BlueShield Association medical policy of the same name along with a review from the MEDLINE database and information from Physician Specialty Societies. The most recent literature review was performed through December 15, 2014. Following is a summary of the key literature.

Overactive Bladder

Systematic Reviews

An updated TEC Assessment on posterior tibial nerve stimulation (PTNS) for treatment of voiding dysfunction was published in December 2013 and concluded that PTNS meets the TEC criteria for treatment of voiding dysfunction.(1) The TEC Assessment included 6 randomized controlled trials (RCTs) and had the following conclusion:

Evidence from randomized placebo-controlled trials supports the clinical efficacy of PTNS applied in the standard 12-week regimen. No concurrently controlled evidence exists from a trial over longer periods of time in maintenance therapy. Although the lack of controlled evidence on maintenance PTNS raises concern whether short-term efficacy is maintained over the long term, the available 12- to 36-month evidence appears consistent with maintained efficacy in relieving symptoms of overactive bladder (OAB) and urinary voiding dysfunction. Adverse event rates, assuming accurate ascertainment, appear limited.

In 2012 and 2013, other systematic reviews of the literature on PTNS for treating overactive bladder were published.(2-5) Only one of these systematic reviews, however, conducted pooled analyses of study results.(2) This review, by Burton et al, conducted a pooled analysis of data from 4 trials (2 of which were abstracts) comparing PTNS with sham treatment. They found a significantly higher risk of successful treatment with PTNS (risk ratio [RR], 7.02; 95% confidence interval [CI], 1.69 to 29.17) compared with a control intervention. The confidence interval was wide, indicating a lack of precision in the pooled estimate. In the pooled analysis, the SUmiT trial contributed 220 of 289 patients (76%). (6)

In 2012, the Agency for Healthcare Research and Quality (AHRQ) Effective Health Care (HEC) Program published a comparative effectiveness review on the broader topic of nonsurgical treatments for urinary incontinence in adult women.(6) The review identified 4 reports of RCTs comparing PTNS and no active treatment in patients with OAB. Two of the 4 articles reported 12-week results of the sham-controlled SUmiT trial; one of these included a subgroup of SUmiT participants and was only published as an abstract. The AHRQ report included a pooled analysis of data from 3 studies that found statistically significantly greater improvement in urinary incontinence in the PTNS group compared with the control group (RR=1.9; 95% CI: 1.1 to 3.2). This pooled analysis included a total of 405 patients; 220 in the SUmiT trial, 150 in the SUmiT trial subanalysis and 35 in a trial by Finazzi-Agro et al. (7) A limit of the analysis in the AHRQ review was that the 150 patients in the SUmiT subanalysis were included twice. The AHRQ report did not discuss evidence on the efficacy of PTNS beyond 12 weeks.

Randomized Controlled Trials

Two key randomized controlled trials (RCTs) published in 2009 and 2010 evaluated percutaneous tibial nerve stimulation for treating patients diagnosed with overactive bladder syndrome.

The first RCT published in 2009 by Peters et al. was an industry-sponsored non-blinded comparison of PTNS and extended-release medication, tolterodine (Detrol LA), in women with overactive bladder syndrome (the OrBIT trial). (8) The study included 100 patients (50 per group); more than 90% were women. Study participants were identified at 11 centers between June 2006 and September 2008. Participants had symptoms of OAB, with at least 8 voids per 24 hours; the mean daily voids for those entering the study were 12.3. A total of 87 of the 100 (87%) patients completed the study, and voiding diary data were available for 84 patients, 41 of 50 (82%) in the PTNS group and 43 of 50 (86%) in the tolterodine group.

The primary outcome was the non-inferiority of PTNS in the mean reduction in the number of voids per 24 hours after 12 weeks of treatment. Non-inferiority was defined as no more than a 20% difference in the mean void reduction. Study findings showed non-inferiority of PTNS based on results for 84 patients. The decrease in number and SD of voids per day was 2.4 (4.0) in the PTNS group and 2.5 (3.9) in the tolterodine group.

The study reported a number of secondary outcomes, with mixed findings. There were no statistically significant differences in the PTNS and tolterodine groups for other symptoms recorded in the voiding diary; this includes mean change in episodes of nocturia (-0.7 and -0.6, respectively), episodes of moderate to severe urgency per day (-2.2 and -2.9, respectively), and episodes of urge incontinence per day (-1.0 and -1.7, respectively). In other secondary outcomes, 35 of 44 patients (79.5%) in the PTNS group and 23 of 42 (54.8%) in the tolterodine group reported symptom improvement or cure. This difference was statistically significant (p=0.01), favoring the PTNS group. However, the proportion of patients reporting symptom improvement (excluding the 3 patients reporting that they were cured) did not differ significantly between groups, 34 of 44 (77.3%) of those receiving PTNS and 21 of 42 (50%) receiving tolterodine. For the adverse event data, responses were obtained in person for the PTNS group in conjunction with their weekly treatment sessions and over the phone for the medication group, using standard checklists. It is not clear how response to treatment or quality-of-life data were collected.

Limitations of the OrBIT trial included the lack of blinding of patients and providers and the lack of comparative data beyond the end of the initial 12-week treatment period. Moreover, there was no sham or placebo group to mitigate the potential bias due to subjective outcomes. In addition, the authors did not clearly define criteria for “improvement” or “cure”, a secondary outcome, and did not report the extent of compliance with medical therapy and used different methods of data collection in the 2 groups for adverse event outcomes and possibly for other self-report outcomes that prevented procedural consistency.

In 2010, MacDiarmid et al. reported 1-year follow-up data for patients from the OrBIT trial who had been assigned to the PTNS group and had responded to the initial course of treatment, defined as reporting symptom improvement at 12 weeks. (9) Thirty-three of the 35 responders were included. They received a mean of 12.1 (SD=4.9) additional treatments between the 12-week and 12-month visits, and there was a median of 17 days between treatments. Data were available for 32 of the 33 (97%) participants at 6 months and 25 of the 33 (76%) participants at 12 months. The mean reduction in number of voids per day from baseline (the original primary outcome of the study) was 3.2 (SD=3.7) at 6 months and 2.8 (SD=3.7) at 12 months. Other voiding diary outcomes at 12 months, based on 25 responses, were mean changes in nocturia episodes of -0.8, in episodes of moderate to severe urgency per day of -3.7, and in episodes of urge incontinence per day of -1.6. As previously noted, this analysis was limited in that no data from the tolterodine group were available to compare long-term outcomes. Another limitation was not all patients in the PTNS group were included in the follow-up analysis, only PTNS responders were eligible. A potential bias is that the initial subjective outcome measure may be subject to the placebo effect. Moreover, patients in the PTNS group who responded to initial treatment may be particularly susceptible to a placebo response and/or may represent those with the best treatment response. Thus, these individuals may also be susceptible to a placebo response during maintenance treatments, especially treatments offered on an as-needed basis

The second key RCT on OAB syndrome, published in 2010 by Peters et al. was also industry-sponsored. (10) This study, known as the SUmiT trial, had a sham-comparison group. The researchers performed a pilot study in healthy volunteers to determine the adequacy of a sham PTNS intervention prior to conducting the actual RCT. (11) Findings were that 10 of 30 volunteers (33%) correctly identified the sham procedure. This percentage is below the 50% that could be expected by chance; the investigators concluded that the procedure was a feasible sham.

The SUmiT trial included patients with OAB syndrome. Eligibility criteria included a score of at least 4 on the overactive bladder questionnaire (OAB-q) short form for urgency, self-report bladder symptoms lasting at least 3 months, and a failed trial of conservative care. Data were collected from 23 centers in the U.S. A total of 220 patients were randomly assigned, 110 to the PTNS group and 110 to the sham group. Both groups received 12 weekly 30-minute intervention sessions. In the sham group, a blunt (placebo) instrument was used to simulate the location and sensation of needle electrode insertion in active treatment. An inactive PTNS surface electrode was used and also 2 active transcutaneous electrical nerve stimulation (TENS) surface electrodes. The TENS unit was used to deliver low-level sensation to simulate the PTNS intervention. The 12-week course of treatment was completed by 103 of 110 (94%) in the PTNS group and 105 of 110 (95%) in the sham group.

The primary study outcome was response to treatment based on a single-item global response assessment (GRA) variable at 13 weeks. Possible responses were that symptoms were markedly worse, moderately worse, mildly worse, the same, slightly improved, moderately improved, or markedly improved. The proportion of patients who responded to treatment based on the GRA (i.e., answered that symptoms were moderately or markedly improved) was 60 of 110 (54.5%) in the PTNS group and 23 of 110 (20.9%) in the sham group; this difference was statistically significant (p<0.001). Intention-to-treat (ITT) analysis was used for the primary endpoint only. Several secondary outcomes also favored the PTNS group. The mean reduction in a symptom severity score (a lower score indicates less severity) was 36.7 (SD=21.5) in the PTNS group and 29.2 (SD=20.0) in the sham group (p=0.01). Similarly, the mean reduction in a quality -of -life scale, the SF-36 (a higher score indicates higher quality of life), was 34.2 (SD=21.3) in the PTNS group and 20.6 (SD=20.6) in the sham group (p=0.006).

For the 4 voiding diary variables used, there was a statistically significant difference between groups favoring PTNS. The mean change from baseline in the number of voids per day was -2.4 (SD=2.5) in the PTNS group and -1.5 (SD=2.4) in the sham group (difference between groups, 0.9 voids per day; p=0.01). The mean change in nocturia episodes was -0.7 (SD=1.2) in the PTNS group and -0.3 (SD=1.4) in the sham group (difference between groups; 0.4 nighttime voids; p=0.04). The mean change in moderate to severe urgency per day was -3.7 in the PTNS group and -2.0 in the sham group (difference between groups, 1.7 episodes; p<0.001). Finally, the mean change in urge incontinence episodes was -1.3 in the PTNS group and -0.3 in the sham group (difference between groups, 1 episode per day; p<0.002). (Standard deviations were not reported for the latter two outcomes.)

Advantages of the SUmiT trial were that it included a sham comparison and the primary end point analysis was intention to treat (ITT). A limitation was that the primary outcome, the GRA, was a single-item subjective measure. For the more objective measures, the voiding diary variables, there was statistically significantly greater benefit with PTNS compared with sham treatment; however, the clinical significance of the difference between the PTNS and sham groups was unclear e.g., on average, there was one fewer episode of urge incontinence a day in the PTNS group. In addition, as in the OrBIT trial, the SUmiT trial only reported comparative data immediately following the initial course of treatment; the study did not evaluate the long-term effectiveness of PTNS. Unlike medication which can be taken on an ongoing basis, PTNS involves an initial 12-week course of treatment followed by maintenance therapy, which to date has not been well-defined. Therefore, the assumption cannot be made that short-term treatment effects will be maintained.

As with the ORBIT trial, there was a SUMIT extension study including only those patients who had been assigned to the PTNS group and initially responded to treatment. The study extension did not collect additional follow-up data from patients in the PTNS group who failed to meet the 12-week primary effectiveness outcome or from patients assigned to the sham-control group. Among the 110 patients assigned to the PTNS group, 60 were initial responders and 50 of these entered the extension study. (12,13) Data were available on 34 patients at 24 months and 29 patients at 36 months. After enrolling in the extension study, patients underwent a 14-week transitional protocol consisting of 2 treatments with a 14-day interval, 2 treatments with a 21-day interval and then 1 treatment after another 28 days. Following this 14-week period, a personal treatment plan was developed for each patient. PTNS treatments were delivered based on the patient’s reporting of symptoms; patients knew that PTNS sessions were available to them as needed when their symptoms increased. Between 6 and 36 months, patients received a median of 1.1 PTNS treatments per month. In a per protocol analysis, compared with baseline, 28 of 29 patients (97%) who completed the 36-month follow-up met the primary efficacy end point of moderate or marked improvement in overall bladder symptoms on the GRA. In addition, compared with baseline, all voiding diary measures were significantly improved in this group of patients at every 6-month follow-up. As mentioned previously in the discussion of the ORBIT extension study, the SUMIT extension study was limited by a lack of follow-up data on the control group and a lack of follow-up data on all participants in the treatment group.

Several other RCTs have been published; none reported on the efficacy of PTNS beyond 12 weeks. Three trials used a parallel group design. In 2010, Finazzi-Agro et al. from Italy conducted a double-blind RCT that included 35 female patients who had urge incontinence and detrusor overactivity on urodynamic testing.(7) Patients were randomly assigned to 30-minute PTNS sessions 3 times per week for 4 weeks (n=18) or sham treatment (n=17). One patient dropped out of the PTNS group and 2 dropped out of the sham group; analysis was not ITT. The primary outcome, percent responders at 4 weeks (defined as at least 50% reduction in incontinent episodes) was attained by 12 of 17 (71%) in the PTNS group and 0 of 15 (0%) in the sham group. Also in 2010, Schreiner et al in Brazil randomized 51 women older than 60 years who complained of urge urinary incontinence to 12 weeks of conservative treatment (Kegel exercises and bladder training) alone (n=26) or conservative treatment plus 12 weekly sessions of PTNS (n=25). (14) The response rate at 12 weeks, defined as a reduction of at least 50% in the number of incontinence episodes reported by the patient in a bladder diary, was 76% in the PTNS group and 27% in the conservative treatment only group (p=0.001). Blinding was not discussed.

In 2012, Gungor Ugurlucan et al. in Turkey published findings of an RCT comparing transvaginal electrical stimulation (ES) (n=38) and PTNS (n=21) in women with OAB. (15) The ES protocol consisted of 20-minute treatments 3 times a week for 6 to 8 weeks. PTNS was performed with an Urgent PC device used for twelve 30-minute weekly sessions. A total of 52 of 59 (88%) patients completed the study. The authors assessed numerous outcome variables and did not specify primary outcomes or adjust p values for multiple comparisons. Four bladder diary variables were reported. From baseline to the end of the treatment period, the groups did not differ significantly at the p<0.05 level in mean change in urgency episodes, nocturia or incontinence episodes. For example, the mean number of urgency episodes was 2.9 (SD=4.1) at baseline and 1.6 (SD=0.5) after treatment in the ES group and 2.0 (SD=3.1) at baseline and 1.3 (SD=0.5) after treatment in the PTNS group (p=0.54). There was a statistically significant difference in daytime frequency. The mean daytime frequency was 7.8 (SD=2.7) at baseline and 5.8 (SD=1.9) after treatment in the ES group and 7.6 (SD=2.6) at baseline and 7.4 (SD=2.9) in the PTNS group (p=0.03). The authors reported that a significantly higher proportion of patients in the ES group described themselves as cured, but they did not provide proportions or p values.

In 2013 Italian researchers Vecchioli-Scaldazza et al. published the results of an RCT using the crossover design. This study included 40 women with OAB. (16) The treatments were PTNS (twice weekly for 6 weeks) and medication (oral solifenacin succinate 5 mg/d for 40 days), given in random order, with a 6-week wash-out period between treatments. Group A received medication first and Group B received PTNS first. The primary efficacy outcome was reduction in the number of voids in a 24-hour period. Thirty of the 40 patients (75%) completed the study. The number of daily voids significantly decreased after each treatment compared with before treatment. In Group A, the mean number of daily voids pre-medication was 11.6 (SD=1.6) and post-medication was 10.0 (SD: 2.1), p=0.004. The mean number of voids pre-PTNS was 11.5 (SD: 1.1) and post-PTNS was 8.5 (SD: 2.3), p<0.001. In Group B, the mean number of voids pre-medication was 11.4 (SD=1.4) and post-medication was 10.4 (SD: 1.8), p=0.008. The mean number of voids pre-PTNS was 11.4 (SD: 1.4) and post-PTNS was 9.4 (SD: 1.9), p<0.001. In addition, secondary outcomes including nocturia urge incontinence and voided volume significantly improved after each treatment compared to pre-treatment values. The authors did not directly compare the efficacy of medication and PTNS.

Neurogenic Bladder

Case Studies

In 2011, 2 case series evaluating PTNS in patients with multiple sclerosis (MS) were published. One study, by Gobbi et al in the United Kingdom included twelve 30-minute treatment sessions with the Urgent PC device. (17) The study included 21 patients with MS who had lower urinary tract symptoms unresponsive to anticholinergics. Overall, urinary symptoms significantly improved at the end of treatment. For example, median daytime frequency decreased from 9 to 6 episodes per day (p=0.04) and median nocturia decreased from 3 to 1 episode per night (p=0.002). The other case series was conducted in France by de Seze et al and used a different protocol. (18) Participants underwent 1 in-clinic treatment session and were then given a TENS device for in-home tibial nerve stimulation; they were told to use the device 20 minutes a day for 3 months. A total of 70 individuals with MS and OAB refractory to medication participated in the study. Compared to baseline, there was a statistically significant reduction in OAB symptoms. For example, the proportion of continent patients increased from 26% to 45% (p=0.005). Both studies were limited by lack of control groups and lack of long-term follow-up; the French study used a different device and different protocol than in the other PTNS studies.

Fecal Incontinence

The Urgent PC Neuromodulation System is not FDA-cleared for the treatment of fecal incontinence. The company’s website states that the treatment can be used for this condition and that the recommended initial course of treatment includes 12 weekly sessions.

In 2014, Horrocks et al. published a systematic review of literature on tibial nerve stimulation (percutaneous and transcutaneous) to treat fecal incontinence. The authors included all study designs and identified a total of 12 articles, 2 RCTs and 10 case series. Six studies evaluated PTNS, 5 evaluated transcutaneous tibial nerve stimulation (TTNS), and 1 of the RCTs compared the 2 treatments. The other RCT compared TTNS with a sham treatment. Three of the 5 case series on PTNS and 1 RCT reported the outcome, 50% or greater reduction in the number of fecal incontinence episodes per week immediately after treatment. In these studies, a median of 71% of patients (range, 63%-82%) reported at least a 50% reduction in episodes. However, this analysis is limited because it lacks a control group and did not include data from all published studies.

The single RCT to date evaluating PTNS for fecal incontinence was published in 2013 by George et al. in the U.K. Thirty patients (28 women) who had failed conservative therapy for fecal incontinence were randomized to PTNS (n=11), TTNS ((n=11) or sham transcutaneous stimulation (n=9). Patients in all groups received a total of 12 treatments given twice-weekly sessions for 6 weeks. (This differs from the PTNS manufacturer’s recommended course of 12 weekly treatments). The primary study end point was at least a 50% reduction in the mean number of incontinence episodes per week at the end of the 6-week treatment period. Only 1 patient did not complete the study, and data were analyzed on an ITT basis. Nine of 11 patients in the PTNS group, 5 of 11 in the TTNS group, and 1 of 8 in the sham group attained the primary end point; the difference among groups was not statistically significant, p=0.035. All of the responders reported no weekly episodes of fecal incontinence after treatment. The study is limited by the small sample size and short-term follow-up.

Ongoing Clinical Trials

A search of on November 17, 2014 identified the following relevant ongoing RCTs on PTNS:

  • Comparison of PTNS and Biofeedback for Fecal Incontinence (NCT01882101): This RCT, sponsored by the Seoul National University Hospital, is randomizing patients with 2 or more weekly episodes of fecal incontinence to 6 weeks of PTNS or EMG biofeedback. The primary outcome is change in the number of weekly episodes of fecal incontinence. The investigators plan to enroll 50 patients. As of November 2014, the study has not yet started enrolling patients.


Percutaneous tibial nerve stimulation (PTNS, also known as posterior tibial nerve stimutation) is a technique of electrical neuromodulation used primarlity for treating voiding dysfunction. The available RCTs report short-term (up to 12 weeks) improvements on measures of urinary incontinence and overactive bladder. Up to 36 months of data are available for some patients enrolled in RCTs who responded to an initial course of treatment. A TEC Assessment published in 2013 found sufficient evidence of short-term efficacy. The Assessment noted the lack of long-term controlled efficacy data, but concluded that the available 12-month to 36-month follow-up data on PTNS responders in the SUmiT and OrBIT trials appeared consistent with maintaining efficacy over the long term. Other systematic reviews of the evidence have found short-term improvements with PTNS and have not evaluated long-term effectiveness. Based on the findings of the 2013 TEC Assessment and support from the American Urological Association guideline, PTNS may be a valid treatment option for patients with OAB who meet clinical criteria. However, there is insufficient evidence that PTNS is effective for other conditions such as fecal incontinence.

Practice Guidelines and Position Statements

In 2014, the American Urological Association (AUA) and the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction published a guideline on diagnosis and treatment of non-neurogenic overactive bladder in adults.(19) The guideline included a statement that clinicians may offer PTNS as a third-line treatment option in carefully selected patients. The statement was rated as Grade C, indicating that the balance of benefits and risks/burdens are uncertain. (This is a revised version of a 2012 guidelines; the statement on PTNS did not change).

The 2005 (reaffirmed 2013) American College of Obstetricians and Gynecologists practice bulletin on treatment of urinary incontinence in women does not address PTNS or other types of nerve stimulation. (20)

U.S. Preventive Services Task Force Recommendations

Not applicable.

Medicare National Coverage

There is no national coverage determination (NCD) found at the time this policy was developed. In the absence of an NCD, coverage decisions are left to the discretion of local Medicare carriers.


  1. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Percutaneous tibial nerve stimulation for the treatment of voiding dysfunction. TEC Assessments 2013; Volume 28. Last accessed February 2014.
  2. Burton C, Sajja A, Latthe PM. Effectiveness of percutaneous posterior tibial nerve stimulation for overactive bladder: a systematic review and meta-analysis. Neurourol Urodyn 2012; 31(8):1206-16.
  3. Levin PJ, Wu JM, Kawasaki A et al. The efficacy of posterior tibial nerve stimulation for the treatment of overactive bladder in women: a systematic review. Int Urogynecol J 2012; 23(11):1591-7.
  4. Moossdorff-Steinhauser HF, Berghmans B. Effects of percutaneous tibial nerve stimulation on adult patients with overactive bladder syndrome: a systematic review. Neurourol Urodyn 2013; 32(3):206-14.
  5. Gaziev G, Topazio L, Iacovelli V et al. Percutaneous tibial nerve stimulation (PTNS) efficacy in the treatment of lower urinary tract dysfunctions: a systematic review. BMC Urol 2013; 13:61.
  6. Shamliyan T, Wyman J, Kane RL. Nonsurgical Treatments for Urinary Incontinence in Adult Women: Diagnosis and Comparative Effectiveness. Agency for Healthcare Research and Quality; Rockville (MD), 2012. Available online at:
  7. Finazzi-Agro E, Petta F, Sciobica F et al. Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial. J Urol 2010; 184(5):2001-6.
  8. Peters K, MacDiarmid SA, Wooldridge LS et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol 2009; 182(3-Jan):1055-61.
  9. MacDiarmid SA, Peters KM, Shobeiri SA et al. Long-term durability of percutaneous tibial nerve stimulation for the treatment of overactive bladder. J Urol 2010; 183(1):234-40.
  10. Peters KM, Carrico DJ, Perez-Marrero P et al. Randomized trial of percutaneous tibial nerve stimulation versus sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol 2010; 183(4):1438-43.
  11. Peters K, Carrico D, Burks F. Validation of a sham for percutaneous tibial nerve stimulation (PTNS). Neurourol Urodyn 2009; 28(1):58-61.
  12. Peters KM, Carrico DJ, MacDiarmid SA et al. Sustained therapeutic effects of percutaneous tibial nerve stimulation: 24-month results of the STEP study. Neurourol Urodyn 2013; 32(1):24-9.
  13. Peters KM, Carrico DJ, Wooldridge LS et al. Percutaneous Tibial Nerve Stimulation for the Long-Term Treatment of Overactive Bladder: 3-Year Results of the STEP Study. J Urol 2013; 189(6):2194-201.
  14. Schreiner L, dos Santos TG, Knorst MR et al. Randomized trial of transcutaneous tibial nerve stimulation to treat urge urinary incontinence in older women. Int Urogynecol J 2010; 21(9):1065-70.
  15. Gungor Ugurlucan F, Onal M, Aslan E et al. Comparison of the effects of electrical stimulation and posterior tibial nerve stimulation in the treatment of overactive bladder syndrome. Gynecol Obstet Invest 2013; 75(1):46-52.
  16. Vecchioli-Scaldazza C, Morosetti C, Berouz A et al. Solifenacin Succinate versus Percutaneous Tibial Nerve Stimulation in Women with Overactive Bladder Syndrome: Results of a Randomized Controlled Crossover Study. Gynecol Obstet Invest 2013; 75(4):230-4.
  17. Gobbi C, Digesu GA, Khullar V et al. Percutaneous posterior tibial nerve stimulation as an effective treatment of refractory lower urinary tract symptoms in patients with multiple sclerosis: preliminary data from a multicentre, prospective, open label trial. Mult Scler 2011; 17(12):1514-9.
  18. De Seze M., Raibaut P, Gallien P et al. Transcutaneous posterior tibial nerve stimulation for treatment of the overactive bladder syndrome in multiple sclerosis: results of a multicenter prospective study. Neurourol Urodyn 2011; 30(3):306-11.
  19. American Urological Association (AUA) and Society of Urodynamics FPMURS. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults/AUA/SUFU guideline. 2012. Available online at: Last accessed November 2014.
  20. American College of Obstetricians and Gynecologists (ACOG). Urinary incontinence in women. ACOG Practice Bulletin, no. 63.2005. Available online at: Last accessed November 2014.
  21. Blue Cross and Blue Shield Association. Posterior Tibial Nerve Stimulation for Voiding Dysfunction. Medical Policy Reference Manual, Policy 7.01.106, 2015.
  22. Horrocks EJ, Thin N, Thaha MA, et al. Systematic review of tibial nerve stimulation to treat faecal incontinence. Br J Surg. 2014;101(5):457-468.
  23. George AT, Kalmar K, Sala S, et al. Randomized controlled trial of percutaneous versus transcutaneous posterior tibial nerve stimulation in faecal incontinence. Br J Surg. 2013;100(3):330-338.







Posterior tibial neurostimulation, percutaneous needle electrode, single treatment, includes programming



Application of a modality to one or more areas; electrical stimulation (unattended)



Application of a modality to one or more areas; electrical stimulation (manual), each 15 minutes

Type of Service



Place of Service










New PR policy to replace 7.01.106. PTNS may be considered medically necessary for selected patients with non-neurogenic OAB when criteria are met, otherwise PTNS is investigational. ICD-9 and ICD-10 diagnosis codes removed; these to not aid adjudication. ICD-9 procedure code 86.09 removed; this does not specifically apply to the policy.


Coding update. ICD-9 procedure code 04.92 removed from policy; this code does not relate to the procedure. Additionally, it is an outpatient procedure; there is no facility charge involved. (Note: ICD-10 code 01HY3MZ also removed based upon the same rationale.)


Update Related Policies. Add 7.01.129


Update Related Policies. Remove 2.01.527 as it was archived.


Annual Review. Policy updated with literature review through December 15, 2014. Title changed to Percutaneous Tibial Nerve Stimulation. “Posterior” changed to “percutaneous” in existing policy statement. Policy statement bullet point of fecal incontinence added as investigational.. References added.

Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. The Company adopts policies after careful review of published peer-reviewed scientific literature, national guidelines and local standards of practice. Since medical technology is constantly changing, the Company reserves the right to review and update policies as appropriate. Member contracts differ in their benefits. Always consult the member benefit booklet or contact a member service representative to determine coverage for a specific medical service or supply. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA).
Ā©2015 Premera All Rights Reserved.